Nanoerythropoietin Is 10-Times More Effective Than Regular Erythropoietin in Neuroprotection in a Neonatal Rat Model of Hypoxia and Ischemia | Zendy

Han Chen | Zendy; Frédéric Spagnoli | Zendy; Michael B. Burris | Zendy; William Rolland | Zendy; Adriel Fajilan | Zendy; Huanyu Dou | Zendy; Jiping Tang | Zendy; John H. Zhang | Zendy

Open Access

Nanoerythropoietin Is 10-Times More Effective Than Regular Erythropoietin in Neuroprotection in a Neonatal Rat Model of Hypoxia and Ischemia

Author(s) -

Han Chen,

Frédéric Spagnoli,

Michael B. Burris,

William Rolland,

Adriel Fajilan,

Huanyu Dou,

Jiping Tang,

John H. Zhang

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.637090

Subject(s) - erythropoietin , neuroprotection , medicine , dose , ischemia , hypoxia (environmental) , pharmacology , stroke (engine) , saline , anesthesia , endocrinology , engineering , mechanical engineering , chemistry , organic chemistry , oxygen

Erythropoietin (EPO) has been demonstrated to possess significant neuroprotective effects in stroke. We determined if the nano-drug form of human recombinant EPO (PLGA-EPO nanoparticles [PLGA-EPO-NP]) can enhance neuroprotection at lower dosages versus human recombinant EPO (r-EPO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research